Aducanumab: Appropriate Use Recommendations

Aducanumab has been approved by the US Food and Drug Administration for treatment of Alzheimer’s disease (AD). Clinicians require guidance on the appropriate use of this new therapy. An Expert Panel was assembled to construct Appropriate Use Recommendations based on the participant populations, cond...

Descripción completa

Detalles Bibliográficos
Autores principales: Cummings, J., Aisen, P., Apostolova, L.G., Atri, A., Salloway, S., Weiner, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835345/
https://www.ncbi.nlm.nih.gov/pubmed/34585212
http://dx.doi.org/10.14283/jpad.2021.41

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835345/
https://www.ncbi.nlm.nih.gov/pubmed/34585212
http://dx.doi.org/10.14283/jpad.2021.41

Ejemplares similares